Merck announced that it acquired OncoEthix, a biotechnology company specializing in oncology drug development, for up to $375 million.
Merck announced on Dec. 18, 2014 that it acquired a Swiss-based, privately held biotechnology company, OncoEthix, specializing in oncology drug development. The acquisition gives Merck OTX015, an investigational BET bromodomain inhibitor designed to treat hematological malignancies and advanced solid tumors. The $110 million acquisition has the potential to add up to $265 million more upon meeting certain clinical and regulatory milestones.
“The acquisition underlines the promise that OTX015 has shown in the treatment of hematological malignancies, and the potential it has for the treatment of advanced solid tumors,” said Bertrand Damour, CEO, OncoEthix, in a press release.
According to the press release, BET proteins could be therapeutic targets in cancer because they regulate key regulators of cancer cell growth and survival. OTX015 showed meaningful clinical activity in Phase I clinical studies in patients with hematological malignancies.
“The potential first-in-class oral BET inhibitor, OTX015, has demonstrated early promising activity in hematological cancers and strategically complements our broad immuno-oncology development program,” said Dr. Roy Baynes, senior vice president, global clinical development, Merck Research Laboratories, in the release.
Source: Merck
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.